2012International Journal of Biotechnology for Wellness IndustriesRequires access

Microbial Metabolism of Rofecoxib, A Selective COX-2 Inhibitor

Orabi

Open publisher page 1 citations

Abstract

Microbial transformation studies of rofecoxib (1), a potent selective cyclooxygenase-2 inhibitor, using sixty microorganisms, mainly fungi and actinomycetes, have revealed that it was metabolized by three microorganisms.Using a standard two-stage screening technique, Cunninghamella echinulata var.echinulata ATCC 9244, Mucor griseocyanus ATCC 1207b, and Rhizopus oryzae ATCC 34121 showed two common more polar metabolites 2 and 3.Moreover, it was apparent that Cunninghamella echinulata var.echinulata was the most efficient microorganism to almost completely metabolize 1, and hence, was selected for preparative scale fermentation.These metabolites were characterized on the basis of their spectral data as 4 -hydroxyrofecoxib (2) and 3 -hydroxyrofecoxib (3).

About this research paper

What this paper is about

Microbial transformation studies of rofecoxib (1), a potent selective cyclooxygenase-2 inhibitor, using sixty microorganisms, mainly fungi and actinomycetes, have revealed that it was metabolized by three microorganisms.Using a standard two-stage screening technique, Cunninghamella echinulata var.echinulata ATCC 9244, Mucor griseocyanus ATCC 1207b, and Rhizopus oryzae ATCC 34121 showed two common more polar metabolites 2 and 3.Moreover, it was apparent that Cunninghamella echinulata var.echinulata was the most efficient microorganism to almost completely metabolize 1, and hence, was selected for preparative scale fermentation.These metabolites were characterized on the basis of their spectral data as 4 -hydroxyrofecoxib (2) and 3 -hydroxyrofecoxib (3).

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Microbial transformation studies of rofecoxib (1), a potent selective cyclooxygenase-2 inhibitor, using sixty microorganisms, mainly fungi and actinomycetes, have revealed that it was metabolized by three microorganisms.Using a standard two-stage screening technique, Cunninghamella echinulata var.echinulata ATCC 9244, Mucor griseocyanus ATCC 1207b, and Rhizopus oryzae ATCC 34121 showed two common more polar metabolites 2 and 3.Moreover, it was apparent that Cunninghamella echinulata var.echinulata was the most efficient microorganism to almost completely metabolize 1, and hence, was selected for preparative scale fermentation.These metabolites were characterized on the basis of their spectral data as 4 -hydroxyrofecoxib (2) and 3 -hydroxyrofecoxib (3).

Key concepts: Rofecoxib, Pharmacology, Chemistry, COX-2 inhibitor, Medicine, Biochemistry, Cyclooxygenase, Enzyme

Related papers

Back to paper searchBrowse research topicsOriginal source
Microbial Metabolism of Rofecoxib, A Selective COX-2 Inhibitor — Research Paper | ScholarLens